Clinical Stage biotech company, Attune Pharmaceuticals focused on the discovery and development of novel, orally administered, small molecule therapeutics for the treatment of rare diseases has announced the completion of a $23 million Series B financing.

Venrock Healthcare Partners led the financing joined by new investor LifeSci Venture Partners, and existing investors RTW Investments, RA Capital, Boxer Capital and Tang Capital. In conjunction with the financing, Rod Wong, managing partner at RTW Investments, has been appointed to Attune’s board of directors.

Proceeds of the Series B round will be used to advance Attune’s pipeline, which includes the ongoing clinical development of ATN-249, a novel orally-administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE).

Bong Koh, partner at Venrock Healthcare Partners said, “We are delighted to have led this round of financing for Attune. ATN-249 has demonstrated a very robust safety, tolerability and pharmacodynamic profile in phase 1 and we look forward to being a partner as the company advances this important new medicine through development.”

Andrew McDonald, CEO of Attune, said, “This financing brings together a syndicate of investors with a deep understanding and long history of supporting companies that develop novel HAE therapeutics. Building upon our recently announced positive Phase 1 data, the Series B enables Attune to rapidly advance our lead clinical program through Phase 2 while also providing capital for our other pre-clinical discovery programs.”

HAE is a rare genetic condition that causes episodic, potentially life-threatening swellings that can affect any part of the body.